SCHEMBL465390

SCHEMBL465390

CCCCCC(CC)C(N)CO

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.59
CYP2D6 P10635 4/20 0.59
SPHK1 Q9NYA1 4/20 0.59
MAPT P10636 4/20 0.59
GMNN O75496 3/20 0.59
POLB P06746 3/20 0.59
BLM P54132 3/20 0.59
CETP P11597 3/20 0.59
UBE2N P61088 3/20 0.59
TP53 P04637 3/20 0.59
THPO P40225 2/20 0.59
CYP1A2 P05177 2/20 0.59
MTOR P42345 1/20 0.59
KDM4E B2RXH2 1/20 0.59
CYP3A4 P08684 1/20 0.59
HTT P42858 1/20 0.59
OPRM1 P35372 1/20 0.44
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
GLA P06280 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21549711 0.93 LMNA (0.50) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL11590246 0.84 LMNA (0.50) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL28446529 0.84 OPRM1 (0.50) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL1168786 0.84 CYP2D6 (0.54) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL29174054 0.82 OPRM1 (0.48) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL29286449 0.82 OPRM1 (0.48) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL11252076 0.80 LMNA (0.47) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL4954386 0.80 OPRM1 (0.46) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL4950681 0.80 OPRM1 (0.46) LMNACYP2D6SPHK1MAPTGMNN
SCHEMBL4946266 0.80 OPRM1 (0.46) LMNACYP2D6SPHK1MAPTGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140073634-A1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) 2014-03-13 US disclosed
US-8481652-B2 Thermoplastic polyamides having polyether amines BASF SE (DE) 2013-07-09 US disclosed
WO-2012007301-A3 FOAM ENHANCEMENT OF FATTY ACYL GLYCINATE SURFACTANTS UNILEVER PLC (GB) 2012-05-10 WO disclosed
EP-2257597-B1 POLYAMIDE NANOCOMPOSITES WITH HYPER- BRANCHED POLYETHERAMINES BASF SE (DE) 2011-11-30 EP disclosed
EP-2227507-B1 THERMOPLASTIC POLYAMIDES HAVING POLYETHER AMINES BASF SE (DE) 2011-08-31 EP disclosed
US-20110021686-A1 POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHERAMINES BASF SE (DE) 2011-01-27 US disclosed
US-20110021687-A1 POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHYLENEIMINES BASF SE (DE) 2011-01-27 US disclosed
US-20110009566-A1 THERMOPLASTIC POLYAMIDES HAVING POLYETHER AMINES BASF SE (DE) 2011-01-13 US disclosed
EP-2257597-A2 POLYAMIDE NANOCOMPOSITES WITH HYPER- BRANCHED POLYETHERAMINES BASF SE (DE) 2010-12-08 EP disclosed
EP-2254949-A1 POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHYLENIMINES BASF SE (DE) 2010-12-01 EP disclosed
EP-2227507-A2 THERMOPLASTIC POLYAMIDES HAVING POLYETHER AMINES BASF SE (DE) 2010-09-15 EP disclosed
WO-2010028975-A2 THERMALLY CONDUCTIVE POLYAMIDE HAVING INCREASED FLOW CAPABILITY BASF SE (DE) 2010-03-18 WO disclosed
WO-2009115535-A2 POLYAMIDE NANOCOMPOSITES WITH HYPER- BRANCHED POLYETHERAMINES BASF SE (DE) 2009-09-24 WO disclosed
WO-2009115536-A1 POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHYLENIMINES BASF SE (DE) 2009-09-24 WO disclosed
WO-2009077492-A2 THERMOPLASTIC POLYAMIDES HAVING POLYETHER AMINES BASF SE (DE) 2009-06-25 WO disclosed
WO-2009050094-A1 THERMOPLASTIC POLYESTER MOLDING COMPOUNDS COMPRISING HIGHLY BRANCHED POLYETHER AMINES BASF SE (DE) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073634-A1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE HIF1AN, HIF1A, EGLN3 LMNA 3216/4885CYP2D6 2361/4885SPHK1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.